Canopy Growth Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Canopy Growth reported Q1 fiscal 2027 revenue of $57.4M, up 13% YoY, with growth across all major businesses. Adjusted EBITDA loss narrowed to $2.3M, down 59% YoY. Management expects positive EBITDA in fiscal 2027, driven by integration of MTL Cannabis and cost savings. Free cash flow worsened to $18.5M, but the company has $241.4M in cash and extended debt maturities to 2031.
Canopy Growth (CGC) is considering another reverse stock split after its shares fell below $1, risking delisting. The company's shares dropped 80% since its last reverse split in December 2023. A shareholder vote on the new split is scheduled for September 25. Canopy reported a 13% sales growth in Q1 2027, with a 68% reduction in losses year-over-year.
Canopy Growth (TSE: WEED, NASDAQ: CGC) will supply four medical cannabis strains to the UK market via GROW Group. This expands its international reach, with Europe contributing 12% of its Q2 revenue. Shares trade near 52-week lows. The company reported a narrowed adjusted loss and increased international revenue, driven by Poland. Competitors Aurora and Tilray have entered the UK market through acquisitions.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CGC (Canopy Growth Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CGC coverage spans financial news, earnings and corporate actions.
In the last 30 days, CGC insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($64K). The most active reporter was ATKINS M SHAN with 1 filing.
Earnings beat on revenue growth and narrowing losses may lift the stock modestly, though continued cash burn tempers upside.
The upcoming reverse split could lift the share price above the $1 listing threshold, reducing delisting risk.
Entry into the UK market could boost international revenue and diversify growth beyond Canada.
Minor insider sell.
Improved earnings and margins suggest a potential upside, but dilution risk remains high.
AlphAI scores every news story that mentions CGC with an AI model for sentiment and relevance, and aggregates insider trades from Canopy Growth Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Canopy Growth reported Q1 fiscal 2027 revenue of $57.4M, up 13% YoY, with growth across all major businesses. Adjusted EBITDA loss narrowed to $2.3M, down 59% YoY. Management expects positive EBITDA in fiscal 2027, driven by integration of MTL Cannabis and cost savings. Free cash flow worsened to $18.5M, but the company has $241.4M in cash and extended debt maturities to 2031.
3 min readCanopy Growth (CGC) is considering another reverse stock split after its shares fell below $1, risking delisting. The company's shares dropped 80% since its last reverse split in December 2023. A shareholder vote on the new split is scheduled for September 25. Canopy reported a 13% sales growth in Q1 2027, with a 68% reduction in losses year-over-year.
2 min readCanopy Growth (TSE: WEED, NASDAQ: CGC) will supply four medical cannabis strains to the UK market via GROW Group. This expands its international reach, with Europe contributing 12% of its Q2 revenue. Shares trade near 52-week lows. The company reported a narrowed adjusted loss and increased international revenue, driven by Poland. Competitors Aurora and Tilray have entered the UK market through acquisitions.
2 min readInsiders sold shares in CrowdStrike (CRWD), Uber (UBER), Snowflake (SNOW), Canopy Growth (CGC), and Medtronic (MDT) last week. CrowdStrike director Roxanne Austin sold 50,000 shares for $11.88M. Uber's Jill Hazelbaker sold 28,170 shares for $2.01M. Snowflake's Jonathan Beaulier sold 12,292 shares for $4.13M. Devon Energy (DVN) CEO Clay Gaspar bought 3,913 shares for $199,876. FuelCell Energy (FCEL) director John Livingston bought 16,404 shares for $246,955.
1 min readCanopy Growth (CGC) reported Q1 2027 net revenue of $81.2M CAD ($58.6M), up 13% YoY, with improved margins and reduced losses. Despite progress, the stock trades below $1 due to U.S. legalization delays and share dilution concerns. The company's market cap is $394M.
2 min readTilray (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB) stocks rose on reports of potential U.S. marijuana reclassification. TLRY +14%, CGC +21%, ACB +7%. Analysts expect ACB to gain 46%, TLRY 28%, CGC 26% from current levels. Companies pursue different growth strategies globally.
2 min readCanopy Growth Corp (CGC) announced an expansion of its medical cannabis offerings in Australia. CGC's P/S ratio is 1.61, below its historical median, and its GF Score™ is 40/100, indicating financial challenges. Insiders have sold $0.4M in shares over the past year. GuruFocus estimates CGC is 39.2% overvalued at $0.97 per share.
2 min readCanopy Growth (TSX: WEED, Nasdaq: CGC) expanded its medical cannabis portfolio in Australia, introducing new pastille and vape formats, as well as expanded oil and softgel offerings. The company aims to meet growing demand for diverse product options, reflecting its global supply chain strength and international growth strategy.
2 min readCanopy Growth (CGC) reported a 13% year-over-year revenue increase to $58.9M in Q1 2027, with improved margins and reduced losses. However, investors reacted muted due to past disappointments and cash burn concerns. Growth included contributions from the MTL Cannabis acquisition, raising questions about organic growth.
2 min readTilray Brands (TLRY) and Canopy Growth (CGC), two major Canadian cannabis retailers, have seen significant stock declines this year. Tilray reported Q4 revenue of $281.7M, up 25% YoY, with cannabis revenue at $71.5M, up 5% YoY. Canopy reported Q1 revenue of CA$81.2M, up 13% YoY. Tilray has lower net debt and is closer to profitability, while Canopy has higher debt and ongoing EBITDA losses.
3 min read
